[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@OncBrothers Oncology Brothers

Oncology Brothers posts on X about matterhorn, paradigm, mos, gain the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXXX +5%
• X Month XXXXXX -XX%
• X Months XXXXXXX +1.10%
• X Year XXXXXXX +70%

Mentions: X #

• X Week XX -XXXX%
• X Month XX -XX%
• X Months XX +83%
• X Year XXX +130%

Followers: XXXXXX #

• X Week XXXXXX +0.60%
• X Month XXXXXX +1.70%
• X Months XXXXXX +11%
• X Year XXXXXX +31%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence travel destinations XX%

Social topic influence matterhorn #63, paradigm 8.33%, mos 8.33%, gain 8.33%, sharma 8.33%, the first XXXX%

Top accounts mentioned or mentioned by @oncoalert @oncupdates @yjanjigianmd @usfda @fdaoncology @ashhematology @sabcssanantonio @drrishabhonco @phsiao4 @stolaney1 @breastoncdoc @beatalleukemia @jeffsharman @chadinabhan @nathanvardi @llsusa @cllireland @cllsupport @rs_flinn @g_mountzios

Top Social Posts

Top posts by engagements in the last XX hours

"Durvalumab (+FLOT) is now @US_FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN We 🗣 this trial findings PDL1 and AEs w/ @YJanjigianMD Full 🗣: Also on Oncology Brothers podcast @OncoAlert @OncUpdates #gism"
X Link 2025-11-26T15:37Z 19.8K followers, 9641 engagements

"One page takeaway/summary from our 🗣 with @YJanjigianMD and #MATTERHORN study that resulted in #Durvalumab @FDAOncology approval on November XX 2025 for resectable GEJ/Gastric adenocarcinoma #OncTwitter #gism #MedTwitter @OncUpdates"
X Link 2025-11-27T14:29Z 19.8K followers, 8358 engagements

"Highlights from #ASH25 #CommunityOnc: #Lymphoma X. #EPCOREFL1 FL X. #CLL17 CLL X. #BRUIN313/314 CLL X. #S1826 HL #Myeloma X. #COBRA X. #MajesTEC3 X. #AQUILA X. #RedirecTT1 #Leukemia X. #PARADIGM @ASH_hematology #lymsm #mmsm #HemeTwitter 1/10"
X Link 2025-12-09T17:26Z 19.8K followers, 10.9K engagements

"Durvalumab + FLOT✂Durva now @FDAOncology ✅ for resectable GEJ/Gastric Ca based off #MATTERHORN study. - Improved OS in all comers (HR: 0.78) - Rate of✂ # of FLOT and AEs (Gr X & 4: 71%) similar in both arms. #OncTwitter @OncoAlert @OncUpdates @YJanjigianMD 👏👏"
X Link 2025-11-25T19:05Z 19.8K followers, 17.8K engagements

"2. Pooled NeoAdj Carboplatin analysis in TNBC from BrighTNess CALGB 40603 GeparSixto: - Carbo in NeoAdj improved pCR (OR 1.89) EFS (HR 0.71) but not OS - In gBRCA EFS was even better (HR 0.50) but no pCR/OS gain. 3/5"
X Link 2025-12-10T01:28Z 19.8K followers, XXX engagements

"3. #RJBC1501: PhIII Adjuvant Carbo to ECtaxane - 5yr DFS XXXX% vs XXXX% (HR 0.66) - OS HR XXXX - Gr 3/4 heme toxicity 4/5"
X Link 2025-12-10T01:28Z 19.8K followers, 1551 engagements